Oncocyte NSCLC Test Gets Local Coverage Determination from Palmetto

The general coverage determination issued by Palmetto covers the use of molecular diagnostic tests as predictive classifiers for NSCLC and are considered reasonable and necessary for patients with non-squamous NSCLC with a tumor smaller than 5 centimeters and no positive lymph nodes. The patient must also be healthy enough to tolerate chemotherapy and be under consideration for adjuvant platinum-containing chemotherapy. The test must be ordered by a physician treating the patient for NSCLC to help decide whether to recommend adjuvant chemotherapy.

The coverage determination is effective for services performed on or after June 14. 

Source: https://www.genomeweb.com/reimbursement-news/oncocyte-nsclc-test-gets-local-coverage-determination-palmetto